Systematic biopsy should not be omitted in the era of combined magnetic resonance imaging/ultrasound fusion-guided biopsies of the prostate.
Int Urol Nephrol
; 53(11): 2251-2259, 2021 Nov.
Article
en En
| MEDLINE
| ID: mdl-34505227
ABSTRACT
PURPOSE:
To evaluate prostate cancer detection rates with classical trans-rectal ultrasound-guided systematic 10-core biopsies (SB), targeted biopsies (TB) guided by magnetic resonance (MR)/US fusion imaging and their combination in biopsy-naïve and patients with previously negative prostate biopsies. We compared pathology results after radical prostatectomy with biopsy findings.METHODS:
Consecutive patients with prostate imaging-reporting and data system lesions grade ≥ 3 submitted to MRI/US-guided TB and subsequent standard 10-core SB between December 2015 and June 2019 were analyzed.RESULTS:
Detection rate (TB- or SB-positive) in 563 included patients (192 naïve, 371 with previous biopsies) was 56.7% (67.7% for the first, 50.9% for repeated biopsies). With TB (disregarding SB), the rates were 41.4%, 52.1% and 35.8%, respectively. With SB (disregarding TB), the rates were 49.1%, 63.0% and 41.8%, respectively. Eventually, 118 patients underwent surgery and clinically significant cancer was found in 111 (94.1%) specimens. Of those, 23 (20.7%) would have been missed had we relied upon a negative TB and 14 (12.6%) would have been missed had we relied upon a negative SB, disregarding a positive finding on the alternative biopsy template.CONCLUSION:
SB should not be omitted since TB and SB combination have higher detection rate of clinically relevant prostate cancer than either procedure alone.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Próstata
/
Neoplasias de la Próstata
Tipo de estudio:
Observational_studies
Límite:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Int Urol Nephrol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Austria